GlassScriptPhysician profile
Titus A Taube
NPI 1891752804
$3,304.19
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $742 · 2021: $711 · 2022: $488 · 2023: $421 · 2024: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $985.89 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $273.82 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $241.27 | 2019-2022 | |
| Lilly USA, LLC | $198.13 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $192.13 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.05 | 2019-2024 | Jardiance, Synjardy |
| Amgen INC. | $142.11 | 2019-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $108.96 | 2019-2020 | |
| Abbott Laboratories | $101.13 | 2021-2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $100.94 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.65 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $88.73 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $72.87 | 2021-2022 | |
| Mannkind Corporation | $59.40 | 2022 | |
| Exact Sciences Corporation | $59.06 | 2023-2024 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $55.11 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $49.00 | 2023 | Spravato |
| Alnylam Pharmaceuticals INC. | $43.80 | 2023 | Givlaari |
| Allergan, INC. | $42.48 | 2020 | |
| Sanofi Pasteur INC. | $39.81 | 2023 | |
| Merck Sharp & Dohme LLC | $36.28 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.10 | 2020 | |
| Astellas Pharma US INC | $18.09 | 2019 | |
| Circassia INC. | $17.16 | 2019 | |
| Nevro Corp. | $16.64 | 2021 | |
| Dexcom, INC. | $15.87 | 2023 | Dexcom G6 Transmitter |
| Linus Health, INC. | $14.15 | 2024 | Core Cognitive Evaluation |
| Eisai INC. | $13.45 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Titus Taube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.